Liraglutide, alone and combined with resveratrol, significantly reduced kidney damage in rats treated with the immunosuppressant cyclosporine A by improving antioxidant status, reducing inflammation, and preventing cell death.
TNF-α negative/mild in liraglutide-treated kidneysWhile cyclosporine-only kidneys showed strong TNF-α inflammation, liraglutide-treated kidneys showed negative to mild staining — demonstrating significant anti-inflammatory protection against drug-induced kidney damage.
What the researchers found
Liraglutide (30 μg/kg/day) and/or resveratrol (20 mg/kg/day) given alongside cyclosporine A (25 mg/kg/day for 21 days) significantly improved kidney function tests and antioxidant activity in treated rats. Both treatments enhanced Bcl-2 levels (anti-apoptotic) while downregulating Bax (pro-apoptotic) in cyclosporine-treated kidneys. TNF-α immunostaining was negative to mildly positive in treated groups versus strongly positive in the cyclosporine-only group, confirming anti-inflammatory effects. Combination treatment (liraglutide + resveratrol) showed benefit across all measured markers.
Why it matters
Cyclosporine nephrotoxicity is a major clinical problem — virtually all transplant patients on cyclosporine develop some degree of kidney damage over time, and it's the leading cause of graft loss after organ transplantation. Finding a co-treatment that protects the kidneys without interfering with immunosuppression could significantly improve outcomes for millions of transplant recipients.
How the study worked
Rats were given cyclosporine A (25 mg/kg orally) for 21 days to induce kidney damage. Treatment groups received liraglutide (30 μg/kg subcutaneously daily), resveratrol (20 mg/kg orally), or both. At study end, serum and kidney tissue were analyzed for kidney function markers, antioxidant status (oxidative stress markers), apoptotic markers (Bcl-2, Bax), and pro-inflammatory markers (TNF-α immunohistochemistry).
What this study cannot tell us
Rat model that may not fully replicate human cyclosporine nephrotoxicity. The 21-day treatment period is short compared to the years of cyclosporine use in transplant patients. The study did not assess whether liraglutide interferes with cyclosporine's immunosuppressive efficacy — a critical question for clinical translation. Specific quantitative data on kidney function improvement were not provided in the abstract. The liraglutide dose used in rats may not translate directly to human doses.
How to read the evidence
This is a preclinical rat study with appropriate controls and multiple outcome measures (functional, biochemical, histological). While the methodology is standard, the small sample sizes typical of rat studies and lack of functional immunosuppression assessment limit the translational significance.
When this study was published
Published in 2024, this study adds to the growing evidence for GLP-1 agonist kidney protection and arrives at a time when clinical interest in using these drugs for non-diabetic kidney disease is expanding rapidly.
The bigger picture
GLP-1 agonists are increasingly recognized for kidney-protective effects beyond diabetes — the FLOW trial showed semaglutide reduces kidney disease progression. This study extends that concept to drug-induced nephrotoxicity, suggesting GLP-1 agonists may protect kidneys through anti-inflammatory and anti-apoptotic mechanisms that are relevant across multiple types of kidney injury.
Questions still open
- Does liraglutide interfere with cyclosporine's immunosuppressive effects, or can they be used safely together in transplant patients?
- Would longer-term co-treatment maintain kidney protection or just delay cyclosporine-induced damage?
- Could GLP-1 agonists protect against nephrotoxicity from other drugs like cisplatin or aminoglycosides?
Common questions
Can liraglutide protect kidneys from medication damage?
Why do transplant drugs damage the kidneys?
Read the original research
Liraglutide and resveratrol alleviated cyclosporin A induced nephrotoxicity in rats through improving antioxidant status, apoptosis and pro-inflammatory markers.
Biochemical and biophysical research communications, 730, 150337
Citation
Kheira, Hend Samy; Elsayed, Gehad Ramadan; El-Adl, Mohamed. (2024). Liraglutide and resveratrol alleviated cyclosporin A induced nephrotoxicity in rats through improving antioxidant status, apoptosis and pro-inflammatory markers.. Biochemical and biophysical research communications, 730, 150337. https://doi.org/10.1016/j.bbrc.2024.150337